Citations

Clear

2303 citation(s) found for "Yu, Edward".

Ligand-dependent and -independent Transforming Growth Factor-β Receptor Recycling Regulated by Clathrin-mediated Endocytosis and Rab11
Mitchell, Hugh , Choudhury, Amit , Pagano, Richard E., Leof, Edward B.

Mayo Clinic

Molecular Biology of the Cell | July 1, 2004 | Volume: 15 | Issue: 9 | Pages: 4166-4178

10.1091/mbc.e04-03-0245 | PMID 15229286 Get It

Proteins in the transforming growth factor-β (TGF-β) family recognize transmembrane serine/threonine kinases known as type I and type II receptors. Binding of TGF-β to receptors results in receptor down-regulation and signaling. Whereas previous work has focused on activities controlling TGF-β signaling, more recent studies have begun to address the trafficking properties of TGF-β receptors. In this report, it is shown that receptors undergo recycling both in the presence and absence of ligand activation, with the rates of internalization and recycling being unaffected by ligand binding. Recycling occurs as receptors are most likely internalized through clathrin-coated pits, and then returned to the plasma membrane via a rab11-dependent, rab4-independent mechanism. Together, the results suggest a mechanism wherein activated TGF-β receptors are directed to a distinct endocytic pathway for down-regulation and clathrin-dependent degradation after one or more rounds of recycling.
Predictors of Cerebral Infarction in Aneurysmal Subarachnoid Hemorrhage
Friedman, Jonathan A., Weigand, Stephen D. , McClelland, Robyn L. , Fulgham, Jimmy R., Manno, Edward M., Atkinson, John L. D., Rabinstein, Alejandro A. , Wijdicks, Eelco F. M.

Mayo Clinic

Stroke | June 25, 2004 | Volume: 35 | Issue: 8 | Pages: 1862-1866

10.1161/01.str.0000133132.76983.8e | PMID 15218156 Get It

Background— Clinical and radiologic predictors of cerebral infarction occurrence and location after aneurysmal subarachnoid hemorrhage have been seldom studied. Methods— We evaluated all patients admitted to our hospital with aneurysmal subarachnoid hemorrhage between 1998 and 2000. Cerebral infarction was defined as a new hypodensity located in a vascular distribution on computed tomography (CT) scan. Results— Fifty-seven of 143 patients (40%) developed a cerebral infarction. On univariate analysis, occurrence of cerebral infarction was associated with a worse World Federation of Neurological Surgeons grade ( P =0.01), use of ventriculostomy catheter ( P =0.01), preoperative vasospasm ( P =0.03), surgical clipping ( P =0.02), symptomatic vasospasm ( P <0.01), and vasospasm on transcranial Doppler ultrasonography (TCD) or repeat angiogram ( P <0.01). On multivariable analysis, only presence of symptoms ascribed to vasospasm ( P <0.01) and evidence of vasospasm on TCD or angiogram predicted cerebral infarction ( P <0.01). TCD and angiogram agreed on the diagnosis of vasospasm in 73% of cases (95% CI, 63% to 81%), but the diagnostic accuracy of this combination of tests was suboptimal for the prediction of cerebral infarction occurrence (sensitivity, 0.72; specificity, 0.68; positive predictive value, 0.67; negative predictive value, 0.72). Location of the cerebral infarction on delayed CT was predicted by neurological symptoms in 74%, by aneurysm location in 77%, and by angiographic vasospasm in 67%. Conclusions— Evidence of vasospasm on TCD and angiogram is predictive of cerebral infarction on CT scan but sensitivity and specificity are suboptimal. Cerebral infarction location cannot be predicted in one quarter to one third of patients by any of the studied clinical or radiological variables.
Estimate of Lung Cancer Mortality From Low-Dose Spiral Computed Tomography Screening Trials: Implications for Current Mass Screening Recommendations
Patz, Edward F. , Swensen, Stephen J., Herndon, James E.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2004 | Volume: 22 | Issue: 11 | Pages: 2202-2206

10.1200/jco.2004.12.046 | PMID 15169809 Get It

Purpose Low-dose computed tomography (CT) has been suggested for lung cancer screening. Several observational trials have published their preliminary results, and some investigators suggest that this technique will save lives. There are no mortality statistics, however, and the current study used published data from these trials to estimate the disease-specific mortality in this high-risk population. Patients and Methods Two nonrandomized CT screening trials were selected from the literature for analysis. The number of trial participants, the number of lung cancers diagnosed per year, and stage distribution of the cancers was recorded. Previously published 5-year survival data were used to calculate the number of predicted lung cancer deaths and estimate the overall lung cancer mortality per 1,000 person-years among participants screened. These statistics were then compared to the previous Mayo Lung Project, which used chest radiographs and sputum cytology for screening high-risk individuals. Results This study estimates the lung cancer mortality is 4.1 deaths per 1,000 person-years in the Mayo Clinic CT screening trial, and is 5.5 deaths per 1,000 person-years in the Early Lung Cancer Action Program trial. These data are similar to the lung cancer mortality of 4.4 deaths per 1,000 person-years in the interventional arm, and 3.9 deaths per 1,000 person-years in the usual-care arm of the previous Mayo Lung Project. Conclusion These data suggest that CT screening could produce similar outcomes to prior chest radiographic trials in this high-risk group. Results from randomized trials are required, however, before the true utility of mass screening with CT for lung cancer can be determined.
Essentials of Medical Genomics. Stuart M. Brown, with contributions by John G. Hay and Harry Ostrer. Hoboken, NJ: Wiley-Liss, Inc., 2003, 256 pp., $89.95, hardcover. ISBN 0-471-21003-X.
Highsmith, W. Edward

Mayo Clinic

Clinical Chemistry | May 25, 2004 | Volume: 50 | Issue: 6 | Pages: 1110-1111

10.1373/clinchem.2003.018986 Get It

Insulation of a G protein-coupled receptor on the plasmalemmal surface of the pancreatic acinar cell.
Roettger, Belinda F., Rentsch, R U, Hadac, Elizabeth M., Hellen, Edward H. , Burghardt, Thomas P. , Miller, Laurence J.

Mayo Clinic

The Journal of cell biology | May 15, 2004 | Volume: 130 | Issue: 3 | Pages: 579-590

10.1083/jcb.130.3.579 | PMID 7622559 Get It

Receptor desensitization is a key process for the protection of the cell from continuous or repeated exposure to high concentrations of an agonist. Well-established mechanisms for desensitization of guanine nucleotide-binding protein (G protein)-coupled receptors include phosphorylation, sequestration/internalization, and down-regulation. In this work, we have examined some mechanisms for desensitization of the cholecystokinin (CCK) receptor which is native to the pancreatic acinar cell, and have found the predominant mechanism to be distinct from these recognized processes. Upon fluorescent agonist occupancy of the native receptor, it becomes "insulated" from the effects of acid washing and becomes immobilized on the surface of the plasma membrane in a time- and temperature-dependent manner. This localization was assessed by ultrastructural studies using a colloidal gold conjugate of CCK, and lateral mobility of the receptor was assessed using fluorescence recovery after photobleaching. Of note, recent application of the same morphologic techniques to a CCK receptor-bearing Chinese hamster ovary cell line demonstrated prominent internalization via the clathrin-dependent endocytic pathway, as well as entry into caveolae (Roettger, B.F., R.U. Rentsch, D. Pinon, E. Holicky, E. Hadac, J.M. Larkin, and L.J. Miller, 1995, J. Cell Biol. 128: 1029-1041). These organelles are not observed to represent prominent compartments for the same receptor to traverse in the acinar cell, although fluorescent insulin is clearly internalized in these cells via receptor-mediated endocytosis. In this work, the rate of lateral mobility of the CCK receptor is observed to be similar in both cell types (1-3 x 10(-10) cm2/s), while the fate of the agonist-occupied receptor is quite distinct in each cell. This supports the unique nature of desensitization processes which occur in a cell-specific manner. A plasmalemmal site of insulation of this important receptor on the pancreatic acinar cell could be particularly effective to protect the cell from processes which might initiate pancreatitis, while providing for the rapid resensitization of this receptor to ensure appropriate pancreatic secretion to aid in nutrient assimilation for the organism.
Differential Trafficking of Transforming Growth Factor-β Receptors and Ligand in Polarized Epithelial Cells
Doré, Jules J.E., Edens, Maryanne, Barnard, J. A., Mitchell, Hugh , Wilkes, Mark C. , Leof, Edward B. , Murphy, Stephen J. , Coffey, Robert J.

Mayo Clinic

Molecular Biology of the Cell | April 12, 2004 | Volume: 15 | Issue: 6 | Pages: 2853-2862

10.1091/mbc.e04-02-0097 | PMID 15075369 Get It

Epithelial cells in vivo form tight cell-cell associations that spatially separate distinct apical and basolateral domains. These domains provide discrete cellular processes essential for proper tissue and organ development. Using confocal imaging and selective plasma membrane domain activation, the type I and type II transforming growth factor-β (TGFβ) receptors were found to be localized specifically at the basolateral surfaces of polarized Madin-Darby canine kidney (MDCK) cells. Receptors concentrated predominantly at the lateral sites of cell-cell contact, adjacent to the gap junctional complex. Cytoplasmic domain truncations for each receptor resulted in the loss of specific lateral domain targeting and dispersion to both the apical and basal domains. Whereas receptors concentrate basolaterally in regions of direct cell-cell contact in nonpolarized MDCK cell monolayers, receptor staining was absent from areas of noncell contact. In contrast to the defined basolateral polarity observed for the TGFβ receptor complex, TGFβ ligand secretion was found to be from the apical surfaces. Confocal imaging of MDCK cells with an antibody to TGFβ1 confirmed a predominant apical localization, with a stark absence at the basal membrane. These findings indicate that cell adhesion regulates the localization of TGFβ receptors in polarized epithelial cultures and that the response to TGFβ is dependent upon the spatial distribution and secretion of TGFβ receptors and ligand, respectively.
Metalloproteinase pregnancy-associated plasma protein A is a critical growth regulatory factor during fetal development
Conover, Cheryl A. , Bale, Laurie K., Overgaard, Michael T. , Johnstone, Edward W., Laursen, Ulla H., Füchtbauer, Ernst‐Martin , Oxvig, Claus , Deursen, Jan van

Mayo Clinic

Development | February 18, 2004 | Volume: 131 | Issue: 5 | Pages: 1187-1194

10.1242/dev.00997 | PMID 14973274 Get It

Pregnancy-associated plasma protein A (PAPPA) is a metzincin superfamily metalloproteinase in the insulin-like growth factor (IGF) system. PAPPA increases IGF bioavailability and mitogenic effectiveness in vitro through regulated cleavage of IGF-binding protein 4 (IGFBP4). To determine its function in vivo, we generated PAPPA-null mice by gene targeting. Mice homozygous for targeted disruption of the PAPPA gene were viable but 60% the size of wild-type littermates at birth. The impact of the mutation was exerted during the early embryonic period prior to organogenesis, resulting in proportional dwarfism. PAPPA, IGF2 and IGFBP4 transcripts co-localized in wild-type embryos, and expression of IGF2 and IGFBP4 mRNA was not altered in PAPPA-deficient embryos. However,IGFBP4 proteolytic activity was completely lacking in fibroblasts derived from PAPPA-deficient embryos, and IGFBP4 effectively inhibited IGF-stimulated mitogenesis in these cells. These results provide the first direct evidence that PAPPA is an essential growth regulatory factor in vivo, and suggest a novel mechanism for regulated IGF bioavailability during early fetal development.
DNA Mutation Detection in a Polymer Microfluidic Network Using Temperature Gradient Gel Electrophoresis
Buch, Jesse , Kimball, Christopher, Rosenberger, Frederick, Highsmith, W. Edward, DeVoe, Don L. , Lee, Cheng S.

Mayo Clinic

Analytical Chemistry | February 13, 2004 | Volume: 76 | Issue: 4 | Pages: 874-881

10.1021/ac034913y | PMID 14961715 Get It

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Recommendations for the Use of Laboratory Tests to Support Poisoned Patients Who Present to the Emergency Department
Wu, Alan H.B. , McKay, Charles, Broussard, Larry A. , Kwong, Tai C., Moyer, Thomas P. , Otten, Edward M., Welch, Shirley L., Wax, Paul M., Hoffman, Robert S.

Mayo Clinic

Clinical Chemistry | February 13, 2004 | Volume: 49 | Issue: 3 | Pages: 357-379

10.1373/49.3.357 | PMID 12600948 Get It

AbstractBackground: Exposure to drugs and toxins is a major cause for patients’ visits to the emergency department (ED).Methods: Recommendations for the use of clinical laboratory tests were prepared by an expert panel of analytical toxicologists and ED physicians specializing in clinical toxicology. These recommendations were posted on the world wide web and presented in open forum at several clinical chemistry and clinical toxicology meetings.Results: A menu of important stat serum and urine toxicology tests was prepared for clinical laboratories who provide clinical toxicology services. For drugs-of-abuse intoxication, most ED physicians do not rely on results of urine drug testing for emergent management decisions. This is in part because immunoassays, although rapid, have limitations in sensitivity and specificity and chromatographic assays, which are more definitive, are more labor-intensive. Ethyl alcohol is widely tested in the ED, and breath testing is a convenient procedure. Determinations made within the ED, however, require oversight by the clinical laboratory. Testing for toxic alcohols is needed, but rapid commercial assays are not available. The laboratory must provide stat assays for acetaminophen, salicylates, co-oximetry, cholinesterase, iron, and some therapeutic drugs, such as lithium and digoxin. Exposure to other heavy metals requires laboratory support for specimen collection but not for emergent testing.Conclusions:Improvements are needed for immunoassays, particularly for amphetamines, benzodiazepines, opioids, and tricyclic antidepressants. Assays for new drugs of abuse must also be developed to meet changing abuse patterns. As no clinical laboratory can provide services to meet all needs, the National Academy of Clinical Biochemistry Committee recommends establishment of regional centers for specialized toxicology testing.
Cell-Type-Specific Activation of PAK2 by Transforming Growth Factor β Independent of Smad2 and Smad3
Wilkes, Mark C. , Garamszegi, Nandor, Leof, Edward B. , Murphy, Stephen J.

Mayo Clinic

Molecular and Cellular Biology | November 11, 2003 | Volume: 23 | Issue: 23 | Pages: 8878-8889

10.1128/mcb.23.23.8878-8889.2003 | PMID 14612425 Get It